Abstract
Long-term monitoring of serum p53 antibody (s-p53-Ab) in patients with advanced cancer during chemotherapy has not been reported. Particularly, very few information was available during the last phase of patient’s life. We report s-p53-Ab changing during chemotherapy for 3 years in a 60-year-old man with stage IV (T2N3M1) esophageal squamous cell carcinoma till the end of his life. s-p53-Ab decreased after first-line chemotherapy and the tumor gradually shrank and stabilized over 6 months. Second-line chemotherapy with docetaxel was initiated after tumor regrowth, followed by third-line chemotherapy with docetaxel and nedaplatin after subsequent regrowth. s-p53-Ab decreased again with treatment response after the second regrowth of the tumor. During the last phase of life, s-p53-Ab did not increase and was not associated with tumor load.
References
Shimada H, Ochiai T (2007) Molecular diagnosis and treatment for esophageal carcinoma with p53. Esophagus 4:165–168
Kato H, Nakajima M, Fukuchi M (2005) Serum p53 antibodies in drainage blood from the azygos vein in patients with esophageal carcinoma. Anticancer Res 25:3231–3235
Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683
Shimada H, Nagata M, Cho A et al (2013) Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. doi:10.1007/s00595-013-0787-y
Shimada H, Nabeya Y, Okazumi S et al (2000) Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 132:41–47
Takahashi K, Miyashita M, Nomura T et al (2007) Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus 20:117–122
Shimada H, Shiratori T, Takeda A et al (2009) Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 33:272–277
Japanese Society for Esophageal Diseases (2007) Guidelines for the clinical and pathologic studies on carcinoma of the esophagus, 10th edn. Kanehara, Tokyo
Shimada H, Ochiai T, Nomura F (2003) Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682–689
Shimada H, Yajima S, Oshima Y et al (2012) Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus 9:131–140
Cai HY, Wang XH, Tian Y et al (2008) Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma. World J Gastroenterol 14:4082–4086
Shimada H, Okazumi S, Takeda A et al (2001) Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today 31:591–596
Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133:24–31
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Shimada, H., Nagata, M., Nabeya, Y. et al. Paradoxical changing of serum p53 antibody titers during chemotherapy for a stage IV esophageal squamous cell carcinoma. Int Canc Conf J 3, 232–236 (2014). https://doi.org/10.1007/s13691-014-0153-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0153-y